entrectinib and Breast-Neoplasms

entrectinib has been researched along with Breast-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for entrectinib and Breast-Neoplasms

ArticleYear
TRK Inhibition with Entrectinib in Metastatic Salivary Secretory Carcinoma (SC): A Case Report.
    Current oncology (Toronto, Ont.), 2022, 05-31, Volume: 29, Issue:6

    NTRK gene fusions are rare oncogenic driver mutations that can be found in a broad range of neoplasms. In secretory carcinoma (SC),

    Topics: Benzamides; Breast Neoplasms; Carcinoma; Gene Fusion; Humans; Indazoles

2022